-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, Johnson & Johnson announced that the latest data from a phase 3b clinical trial showed that in the prevention of COVID-19-related hospitalizations, a single-dose COVID-19 vaccine (Ad26.
COV2.
S) under investigation was injected.
The homologous booster needle achieves 85% vaccine effectiveness
.
The test results show that in South Africa, where Omicron has become the dominant variant of the epidemic, the vaccine booster successfully reduced the risk of medical workers being hospitalized due to the new coronavirus infection
.
Ad26.
COV2.
S developed by Johnson & Johnson is a new coronavirus vaccine that uses adenovirus serotype 26 (Ad26) vector to express the new coronavirus spike protein
.
The latest data of the Phase 3 clinical trial (n=227310) showed that when subjects completed the initial two injections 6-9 months after the booster injection, the effectiveness of the vaccine was 63% (95%) from 0-13 days.
% CI, 31-81%), increased to 84% (95% CI, 67-92%) at 14-27 days after booster vaccination, and 85% (95% CI, 54-95%) at 1-2 months )
.
Previous research conducted by WuXi AppTec's content team found that the Omicron variant is related to immune escape after previous infections
.
In other words, even if you have previously been infected with the new coronavirus, the immunity generated may not be enough to completely resist the new Omicron variant
.
The researchers pointed out that the increase in CD8-positive T cells caused by the intensified needle may be the key to the high level of effectiveness in protecting against severe new crown infection and hospitalization
.
"Experimental data proves that in regions where the Omicron variant is dominant, the enhanced injection of Johnson & Johnson's new crown vaccine provides 85% of the effectiveness of preventing hospitalization
.
" The protective effect may be due to the strong T cell response induced by Johnson & Johnson 's new crown vaccine
.
In addition, these data also show that Omicron does not affect the T cell response generated by our vaccine
.
"Reference: [1] Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant.
Retrieved December 30, 2021, from https:// hospitalization-in-south-africa-when-omicron-was-dominant disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
COV2.
S) under investigation was injected.
The homologous booster needle achieves 85% vaccine effectiveness
.
The test results show that in South Africa, where Omicron has become the dominant variant of the epidemic, the vaccine booster successfully reduced the risk of medical workers being hospitalized due to the new coronavirus infection
.
Ad26.
COV2.
S developed by Johnson & Johnson is a new coronavirus vaccine that uses adenovirus serotype 26 (Ad26) vector to express the new coronavirus spike protein
.
The latest data of the Phase 3 clinical trial (n=227310) showed that when subjects completed the initial two injections 6-9 months after the booster injection, the effectiveness of the vaccine was 63% (95%) from 0-13 days.
% CI, 31-81%), increased to 84% (95% CI, 67-92%) at 14-27 days after booster vaccination, and 85% (95% CI, 54-95%) at 1-2 months )
.
Previous research conducted by WuXi AppTec's content team found that the Omicron variant is related to immune escape after previous infections
.
In other words, even if you have previously been infected with the new coronavirus, the immunity generated may not be enough to completely resist the new Omicron variant
.
The researchers pointed out that the increase in CD8-positive T cells caused by the intensified needle may be the key to the high level of effectiveness in protecting against severe new crown infection and hospitalization
.
"Experimental data proves that in regions where the Omicron variant is dominant, the enhanced injection of Johnson & Johnson's new crown vaccine provides 85% of the effectiveness of preventing hospitalization
.
" The protective effect may be due to the strong T cell response induced by Johnson & Johnson 's new crown vaccine
.
In addition, these data also show that Omicron does not affect the T cell response generated by our vaccine
.
"Reference: [1] Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant.
Retrieved December 30, 2021, from https:// hospitalization-in-south-africa-when-omicron-was-dominant disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
